Arrowhead Pharmaceuticals Net Worth
Arrowhead Pharmaceuticals Net Worth Breakdown | ARWR |
Arrowhead Pharmaceuticals Net Worth Analysis
Arrowhead Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Arrowhead Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Arrowhead Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Arrowhead Pharmaceuticals' net worth analysis. One common approach is to calculate Arrowhead Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Arrowhead Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Arrowhead Pharmaceuticals' net worth. This approach calculates the present value of Arrowhead Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Arrowhead Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Arrowhead Pharmaceuticals' net worth. This involves comparing Arrowhead Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Arrowhead Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Arrowhead Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arrowhead Pharmaceuticals' net worth research are outlined below:
| Arrowhead Pharmaceuticals had very high historical volatility over the last 90 days | |
| Arrowhead Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.55 M. Net Loss for the year was (609.69 M) with profit before overhead, payroll, taxes, and interest of 19.65 M. | |
| Arrowhead Pharmaceuticals currently holds about 416.5 M in cash with (462.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93. | |
| Arrowhead Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Insider Selling Arrowhead Pharmaceuticals, Inc. Director Sells 959 Shares of Stock - MarketBeat |
Arrowhead Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arrowhead Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arrowhead Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Arrowhead Pharmaceuticals Target Price Consensus
Arrowhead target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Arrowhead Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most Arrowhead analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Arrowhead stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Arrowhead Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationArrowhead Pharmaceuticals Target Price Projection
Arrowhead Pharmaceuticals' current and average target prices are 19.88 and 47.50, respectively. The current price of Arrowhead Pharmaceuticals is the price at which Arrowhead Pharmaceuticals is currently trading. On the other hand, Arrowhead Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Arrowhead Pharmaceuticals Market Quote on 1st of February 2025
Target Price
Analyst Consensus On Arrowhead Pharmaceuticals Target Price
Know Arrowhead Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arrowhead Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arrowhead Pharmaceuticals backward and forwards among themselves. Arrowhead Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Arrowhead Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.6 M | Norges Bank | 2024-06-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.3 M | Goldman Sachs Group Inc | 2024-09-30 | 1.3 M | Citadel Advisors Llc | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | Bank Of New York Mellon Corp | 2024-09-30 | 866.4 K | Woodline Partners Lp | 2024-09-30 | 865.8 K | Western Financial Corp/ca | 2024-12-31 | 820.2 K | Blackrock Inc | 2024-09-30 | 15.8 M | Vanguard Group Inc | 2024-09-30 | 12.2 M |
Follow Arrowhead Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.53 B.Market Cap |
|
Project Arrowhead Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.47) | (0.50) | |
| Return On Equity | (3.72) | (3.53) |
When accessing Arrowhead Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Arrowhead Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arrowhead Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Arrowhead Pharmaceuticals' management efficiency
Arrowhead Pharmaceuticals has return on total asset (ROA) of (0.4072) % which means that it has lost $0.4072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5184) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/01/2025, Return On Tangible Assets is likely to drop to -0.5. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 02/01/2025, Non Current Assets Total is likely to grow to about 536.5 M, while Net Tangible Assets are likely to drop slightly above 202.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.44 | 1.51 | |
| Tangible Book Value Per Share | 1.37 | 1.44 | |
| Enterprise Value Over EBITDA | (4.37) | (4.59) | |
| Price Book Value Ratio | 11.26 | 11.82 | |
| Enterprise Value Multiple | (4.37) | (4.59) | |
| Price Fair Value | 11.26 | 11.82 | |
| Enterprise Value | 3.1 B | 3.3 B |
Effective management at Arrowhead Pharmaceuticals has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue 664.5505 | Revenue | Quarterly Revenue Growth (0.94) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arrowhead Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arrowhead Pharmaceuticals Corporate Filings
| 29th of January 2025 Other Reports | ViewVerify | |
F4 | 27th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
8K | 18th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Arrowhead Pharmaceuticals Earnings Estimation Breakdown
The calculation of Arrowhead Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Arrowhead Pharmaceuticals is estimated to be -0.7194 with the future projection ranging from a low of -1.43 to a high of 2.91. Please be aware that this consensus of annual earnings estimates for Arrowhead Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.43 Lowest | Expected EPS | 2.91 Highest |
Arrowhead Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Arrowhead Pharmaceuticals' value are higher than the current market price of the Arrowhead Pharmaceuticals stock. In this case, investors may conclude that Arrowhead Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Arrowhead Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 15 | 51.15% | -1.37 | -0.7194 | -5.0 |
Arrowhead Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Arrowhead Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Arrowhead Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Arrowhead Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Arrowhead Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Arrowhead Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Arrowhead Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Arrowhead Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Arrowhead Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-27 | 2024-09-30 | -0.922 | -1.37 | -0.448 | 48 | ||
2024-08-08 | 2024-06-30 | -0.55 | -1.38 | -0.83 | 150 | ||
2024-05-09 | 2024-03-31 | -0.16 | -1.02 | -0.86 | 537 | ||
2024-02-06 | 2023-12-31 | -0.82 | -1.24 | -0.42 | 51 | ||
2023-11-29 | 2023-09-30 | -0.6 | -1.02 | -0.42 | 70 | ||
2023-08-07 | 2023-06-30 | -0.65 | -0.96 | -0.31 | 47 | ||
2023-05-02 | 2023-03-31 | -0.64 | 0.45 | 1.09 | 170 | ||
2023-02-06 | 2022-12-31 | 0.44 | -0.39 | -0.83 | 188 | ||
2022-11-28 | 2022-09-30 | -0.17 | -0.81 | -0.64 | 376 | ||
2022-08-04 | 2022-06-30 | -0.51 | -0.68 | -0.17 | 33 | ||
2022-05-10 | 2022-03-31 | -0.08 | 0.41 | 0.49 | 612 | ||
2022-02-02 | 2021-12-31 | -0.45 | -0.6 | -0.15 | 33 | ||
2021-11-22 | 2021-09-30 | -0.11 | -0.61 | -0.5 | 454 | ||
2021-08-05 | 2021-06-30 | -0.2 | -0.29 | -0.09 | 45 | ||
2021-05-04 | 2021-03-31 | -0.13 | -0.26 | -0.13 | 100 | ||
2021-02-04 | 2020-12-31 | 0.12 | -0.2 | -0.32 | 266 | ||
2020-11-23 | 2020-09-30 | 0.12 | -0.48 | -0.6 | 500 | ||
2020-08-05 | 2020-06-30 | -0.12 | -0.13 | -0.01 | 8 | ||
2020-05-07 | 2020-03-31 | -0.11 | -0.2 | -0.09 | 81 | ||
2020-02-05 | 2019-12-31 | -0.01 | -0.03 | -0.02 | 200 | ||
2019-11-25 | 2019-09-30 | 0.16 | 0.11 | -0.05 | 31 | ||
2019-08-05 | 2019-06-30 | 0.29 | 0.21 | -0.08 | 27 | ||
2019-05-08 | 2019-03-31 | 0.19 | 0.24 | 0.05 | 26 | ||
2019-02-07 | 2018-12-31 | 0.54 | 0.13 | -0.41 | 75 | ||
2018-12-11 | 2018-09-30 | -0.11 | -0.12 | -0.01 | 9 | ||
2018-08-07 | 2018-06-30 | -0.18 | -0.18 | 0.0 | 0 | ||
2018-05-08 | 2018-03-31 | -0.18 | -0.18 | 0.0 | 0 | ||
2018-02-09 | 2017-12-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2017-12-12 | 2017-09-30 | -0.1 | -0.15 | -0.05 | 50 | ||
2017-08-03 | 2017-06-30 | -0.14 | -0.07 | 0.07 | 50 | ||
2017-05-03 | 2017-03-31 | -0.12 | -0.08 | 0.04 | 33 | ||
2017-02-06 | 2016-12-31 | -0.2 | -0.17 | 0.03 | 15 | ||
2016-12-14 | 2016-09-30 | -0.2 | -0.34 | -0.14 | 70 | ||
2016-08-09 | 2016-06-30 | -0.37 | -0.32 | 0.05 | 13 | ||
2016-05-10 | 2016-03-31 | -0.37 | -0.35 | 0.02 | 5 | ||
2016-02-09 | 2015-12-31 | -0.41 | -0.32 | 0.09 | 21 | ||
2015-12-14 | 2015-09-30 | -0.39 | -0.41 | -0.02 | 5 | ||
2015-08-04 | 2015-06-30 | -0.38 | -0.27 | 0.11 | 28 | ||
2015-05-11 | 2015-03-31 | -0.34 | -0.33 | 0.01 | 2 | ||
2015-02-09 | 2014-12-31 | -0.34 | -0.41 | -0.07 | 20 | ||
2014-11-25 | 2014-09-30 | -0.24 | -0.33 | -0.09 | 37 | ||
2014-08-12 | 2014-06-30 | -0.22 | -0.22 | 0.0 | 0 | ||
2014-05-06 | 2014-03-31 | -0.2 | -0.31 | -0.11 | 55 | ||
2014-02-04 | 2013-12-31 | -0.2 | -0.28 | -0.08 | 40 | ||
2013-12-18 | 2013-09-30 | -0.18 | -0.38 | -0.2 | 111 | ||
2010-08-12 | 2010-06-30 | -0.45 | -0.1 | 0.35 | 77 | ||
2010-05-13 | 2010-03-31 | -0.41 | -0.3 | 0.11 | 26 | ||
2010-02-11 | 2009-12-31 | -0.55 | -0.3 | 0.25 | 45 |
Arrowhead Pharmaceuticals Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Kenneth Myszkowski | Chief Officer | Profile | |
| Javier MD | Chief Officer | Profile | |
| Bruce MD | Chief Scientist | Profile | |
| Vincent CFA | Head VP | Profile | |
| MBA MD | Chief Medicine | Profile | |
| Tracie Oliver | Chief Officer | Profile |
Already Invested in Arrowhead Pharmaceuticals?
The danger of trading Arrowhead Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arrowhead Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arrowhead Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arrowhead Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.